Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4HF-05
- Development stage
- Preclinical
- Lead developer
- 4HF Biotec
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
4HF-05 is an early-stage small molecule drug conjugate (SMDC) being developed by 4HF Biotec for the treatment of small cell lung cancer (SCLC). As an SMDC, it is designed to utilize a small molecule ligand to target specific receptors or proteins overexpressed on cancer cells, delivering a cytotoxic payload directly to the tumor site while sparing healthy tissue. The company utilizes an AI-driven platform for cancer target identification to develop its pipeline of SMDCs. 4HF-05 is currently in the discovery phase, specifically undergoing in silico and medicinal chemistry optimization to refine its targeting and therapeutic profile.
Beyond the preview
Go deeper on 4HF-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4HF-05.